Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
July 21, 2020
The Center for Biosimilars
On July 21, Axinn partner Ted Mathias participated in a video interview with The Center for Biosimilars. They discussed the differences in how insulins will be regulated under the Biologics Price Competition and Innovation Act (BPCIA) versus the Hatch-Waxman Act and the new challenges follow-on manufacturers will face.
Click here to access the interview.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
Informa Antitrust Midwest 2026
Speaking Engagement
Antitrust
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2026
Sponsorship
AHLA Annual Meeting & In-House Counsel Program
Sponsorship
Antitrust
Gleiss Lutz Annual Antitrust Law Conference
Speaking Engagement
Antitrust
South Asian Bar Association of North America Annual Conference
Sponsorship
Axinn Named Antitrust Law Firm of the Year at the Chambers USA Awards 2026
News
Antitrust
Chambers USA Awards 2026
Sponsorship
Antitrust
ABA 2026 Antitrust International Cartel Workshop
Speaking Engagement
Antitrust
Axinn Earns Recognition in the Legal 500 2026 U.S. Guide for Antitrust and Litigation
News
Antitrust
Axinn Attorneys Featured in 2026 Lawdragon 500 X – The Next Generation Guide
News
Antitrust
